Creating a network for precision oncology in central-southern Italy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

COESIT aims to establish a network of reference laboratories in central-southern Italy to enhance the genetic and molecular characterization of tumors. The initiative involves upgrading laboratory technologies, standardizing sequencing procedures, and creating a shared database that integrates sequencing data with clinicopathological information. This collaborative effort will facilitate research into genetic alterations in tumors and help identify biomarkers for precision and personalized oncology. The study will collect both retrospective and prospective data from cancer patients in the region.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Cancer patients
* Patients from the central-southern regions

Exclusion Criteria:

\-

Where it's running

• Istituto Nazionale Tumori di Napoli - IRCCS - Fondazione G. Pascale
  Naples, Italy Recruiting

Study contacts

• Principal investigator: Antonella De Luca — Istituto Nazionale Tumori di Napoli - IRCCS - Fondazione G. Pascale
• Study coordinator: Antonella De Luca
• Email: a.deluca@istitutotumori.na.it
• Phone: 08117770603

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• 4D MRI parameters linked to cardiovascular and cancer disease outcomes

  This study tests whether 4D MRI measurements can predict how cardiovascular diseases and cancer will progress in adults undergoing routine cardiac MRI at a single Korean hospital.

  Recruiting Ulsan University Hospital · Ulsan, Ulsan · NCT07678606

• Intratumoral injection of mechanically reprogrammed macrophage-derived exosomes for advanced solid tumors

  This trial will test whether injecting mechanically reprogrammed macrophage-derived exosomes directly into tumors is safe and tolerable in adults 18–65 with advanced solid tumors who have no standard treatment options.

  Recruiting Phase 1 West China Hospital · Chengdu, Sichuan · NCT07563972

• EMDR group program with optional individual EMDR for people with cancer

  This project will try EMDR group therapy plus optional individual EMDR to reduce PTSD symptoms and psychological distress in people diagnosed with cancer.

  Recruiting Università Cattolica di Milano · Milan · NCT07447089

• KLN-1010 gene therapy for relapsed or refractory multiple myeloma

  This Phase 1 trial will try KLN-1010, an in vivo CAR‑T gene therapy, to see if it is safe and can be given at a tolerable dose for people with relapsed or refractory multiple myeloma who have had at least three prior therapies.

  Recruiting at 11 sites Phase 1 Kelonia Therapeutics, Inc. · Duarte, California and 10 other locations · NCT07075185

• Adaptive care for Chinese cancer survivors with insomnia

  This study is testing whether a web-based therapy for insomnia or an online exercise program can help Chinese cancer survivors sleep better, and if those who still have trouble can benefit from more intensive face-to-face support.

  Recruiting The University of Hong Kong · Hong Kong · NCT06813235

• Positive activities for Asian American cancer patients and their caregivers

  This study is testing a new program that encourages positive activities for Asian American cancer patients and their caregivers to see if it helps improve their mental well-being.

  Recruiting Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT06782581

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.